Enveric Biosciences Inc
Change company Symbol lookup
Select an option...
ENVB Enveric Biosciences Inc
AHI Advanced Health Intelligence Ltd
OTLK Outlook Therapeutics Inc
PBHC Pathfinder Bancorp Inc (MARYLAND)
CMA Comerica Inc
IART Integra Lifesciences Holdings Corp
ARKW.SO ARK Next Generation Internet ETF
AGNC Agnc Investment Corp
HCA HCA Healthcare Inc
LGHL Lion Group Holding Ltd
Go

Health Care : Pharmaceuticals | Small Cap Value

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.

Postmarket

Last Trade: Delayed
$2.55

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: 0.01 (0.39%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $2.54

Day's Change: -0.16 (-5.93%)

Bid close: --

Ask close: --

B/A Size: --

Day's High: 2.71

Day's Low: 2.26

Volume (Below Average) Volume: 34,646 10-day average volume: 42,395: 34,646

Yesterday's News, October 03, 2023
8:00 am ET	Enveric Biosciences Announces its Psybrary(TM) Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today...(BusinessWire)
September 27, 2023
8:01 am ET	Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today...(BusinessWire)
September 20, 2023
8:00 am ET	Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders, today...(BusinessWire)
September 18, 2023
8:00 am ET	Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders, today...(BusinessWire)
September 11, 2023
8:00 am ET	Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today...(BusinessWire)
September 05, 2023
8:00 am ET	Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today...(BusinessWire)
August 30, 2023
8:01 am ET	Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today...(BusinessWire)
August 28, 2023
11:04 am ET	Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today...(BusinessWire)
8:00 am ET	Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today...(BusinessWire)
August 24, 2023
8:00 am ET	Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB)(Globe Newswire)
August 21, 2023
8:00 am ET	Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today...(BusinessWire)
August 14, 2023
8:00 am ET	Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders...(BusinessWire)
July 24, 2023
8:00 am ET	Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today...(BusinessWire)
July 17, 2023
8:00 am ET	Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 --Outcome of animal studies indicate potential to reduce GI upset and vomiting as well as rapid onset of action and systemic clearance, improving on PK characteristics of psilocybin Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a...(BusinessWire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Postmarket

Change Since Close

Market Hours